/SLDB
SLDB Stock - Solid Biosciences Inc.
Healthcare|BiotechnologyNASDAQ
$5.94+12.50%
+$0.66 (+12.50%) • Dec 19
68
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.93
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.1
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+110.4%upside
Target: $12.50
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for SLDB
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$5.88 – $6.00
TARGET (TP)$12.50
STOP LOSS$5.46
RISK/REWARD1:13.7
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta2.98
52W High$7.37
52W Low$2.41
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | $8.09M | $13.62M | N/A |
| Gross Profit | $-2,455,000 | $-2,581,000 | $8.09M | $13.62M | $-3,922,000 |
| Gross Margin | N/A | N/A | 100.0% | 100.0% | N/A |
| Operating Income | $-129,728,000 | $-104,315,000 | $-106,452,000 | $-72,254,000 | $-86,462,000 |
| Net Income | $-124,697,000 | $-96,015,000 | $-85,981,000 | $-72,188,000 | $-88,290,000 |
| Net Margin | N/A | N/A | -1062.3% | -530.0% | N/A |
| EPS | $-3.06 | $-4.83 | $-10.10 | $-10.14 | $-25.50 |
Company Overview
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate for the treatment of duchenne muscular dystrophy. It also engages in developing of platform technologies, including dual gene expression, a technology for packaging multiple transgenes into one vector, as well as novel capsids. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
9
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
9 Bullish0 Neutral/Bearish
Price Targets
$17
Average Target
↑ 193.2% Upside
Now
$9
Low
$17
Average
$40
High
Based on 12 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 4th 2025 | Needham | Initiation | Buy | $16 |
| June 26th 2025 | Citigroup | Initiation | Buy | $14 |
| January 8th 2025 | Truist | Initiation | Buy | $16 |
| December 13th 2024 | Wedbush | Initiation | Outperform | $16 |
| December 10th 2024 | JMP Securities | Initiation | Mkt Outperform | $15 |
| July 15th 2024 | JP Morgan | Upgrade | Overweight | $15← $10 |
| June 24th 2024 | Leerink Partners | Upgrade | Outperform | $12 |
| May 31st 2024 | Piper Sandler | Resumed | Overweight | $20 |
| March 28th 2024 | William Blair | Initiation | Outperform | $40 |
| March 15th 2024 | Citigroup | Initiation | Buy | $16 |
| March 14th 2024 | Piper Sandler | Upgrade | Overweight | $20← $8 |
| December 8th 2023 | H.C. Wainwright | Initiation | Buy | $9 |
Earnings History & Surprises
SLDBBeat Rate
56%
Last 18 quarters
Avg Surprise
+4.8%
EPS vs Estimate
Beats / Misses
10/8
Last 12 quarters
Latest EPS
$-0.48
Q4 2025
EPS Surprise History
Q1 24
+1.0%
$-1.00vs$-1.01
Q2 24
-12.3%
$-0.64vs$-0.57
Q3 24
+10.3%
$-0.61vs$-0.68
Q4 24
-17.9%
$-0.79vs$-0.67
Q1 25
-12.7%
$-0.89vs$-0.79
Q2 25
-11.3%
$-0.59vs$-0.53
Q3 25
+17.6%
$-0.42vs$-0.51
Q4 25
-14.3%
$-0.48vs$-0.42
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 13, 2026 | — | — | — | — |
Q1 2026 | Mar 5, 2026 | $-0.48 | — | — | — |
Q4 2025 | Nov 3, 2025 | $-0.42 | $-0.48 | -14.3% | ✗ MISS |
Q3 2025 | Aug 12, 2025 | $-0.51 | $-0.42 | +17.6% | ✓ BEAT |
Q2 2025 | May 15, 2025 | $-0.53 | $-0.59 | -11.3% | ✗ MISS |
Q1 2025 | Mar 6, 2025 | $-0.79 | $-0.89 | -12.7% | ✗ MISS |
Q4 2024 | Nov 6, 2024 | $-0.67 | $-0.79 | -17.9% | ✗ MISS |
Q3 2024 | Aug 13, 2024 | $-0.68 | $-0.61 | +10.3% | ✓ BEAT |
Q2 2024 | May 15, 2024 | $-0.57 | $-0.64 | -12.3% | ✗ MISS |
Q1 2024 | Mar 13, 2024 | $-1.01 | $-1.00 | +1.0% | ✓ BEAT |
Q4 2023 | Nov 8, 2023 | $-1.20 | $-1.05 | +12.5% | ✓ BEAT |
Q3 2023 | Aug 14, 2023 | $-1.52 | $-1.25 | +17.8% | ✓ BEAT |
Q2 2023 | May 11, 2023 | $-1.83 | $-1.54 | +15.8% | ✓ BEAT |
Q1 2023 | Mar 23, 2023 | $-2.70 | $-0.68 | +74.8% | ✓ BEAT |
Q4 2022 | Nov 10, 2022 | $-2.59 | $-2.71 | -4.6% | ✗ MISS |
Q3 2022 | Aug 11, 2022 | $-3.15 | $-3.30 | -4.8% | ✗ MISS |
Q2 2022 | Apr 27, 2022 | $-2.70 | $-3.30 | -22.2% | ✗ MISS |
Q1 2022 | Mar 14, 2022 | $-3.00 | $-2.55 | +15.0% | ✓ BEAT |
Q4 2021 | Nov 3, 2021 | $-2.85 | $-2.40 | +15.8% | ✓ BEAT |
Q3 2021 | Aug 16, 2021 | $-2.70 | $-2.55 | +5.6% | ✓ BEAT |
Latest News
Solid Biosciences Announces Data From Proprietary Capsid AAV-SLB101 And Its Cardiac Gene Therapy Pipeline At Global CardioVascular Clinical Trialists
➖ NeutralBenzinga•Dec 8, 2025, 01:03 PM
Solid Biosciences shares are trading higher after Needham initiated coverage on the stock with a Buy rating and announced a price target of $16.
📈 PositiveBenzinga•Dec 4, 2025, 05:35 PM
Needham Initiates Coverage On Solid Biosciences with Buy Rating, Announces Price Target of $16
📈 PositiveBenzinga•Dec 4, 2025, 12:02 PM
Solid Biosciences Announces The FDA Grants Rare Pediatric Disease Designation For SGT-212, Its Investigational Gene Therapy For Friedreich's Ataxia
📈 PositiveBenzinga•Dec 1, 2025, 01:02 PM
Solid Biosciences Announces Non-Exclusive Worldwide License And Collaboration Agreement With Andelyn For Use Of Solid's Proprietary, Next-Gen Capsid, AAV-SLB101
📈 PositiveBenzinga•Nov 17, 2025, 01:13 PM
Solid Biosciences' SGT-003 Gene Therapy For Duchenne Muscular Dystrophy Granted Innovation Passport Under New Innovative Licensing And Access Pathway
📈 PositiveBenzinga•Nov 6, 2025, 01:27 PM
Citigroup Maintains Buy on Solid Biosciences, Lowers Price Target to $14
➖ NeutralBenzinga•Nov 5, 2025, 08:42 PM•Also:
JP Morgan Maintains Overweight on Solid Biosciences, Lowers Price Target to $11
➖ NeutralBenzinga•Nov 5, 2025, 08:16 PM
Barclays Maintains Overweight on Solid Biosciences, Lowers Price Target to $9
➖ NeutralBenzinga•Nov 4, 2025, 02:01 PM•Also:
Chardan Capital Maintains Buy on Solid Biosciences, Maintains $15 Price Target
📈 PositiveBenzinga•Nov 4, 2025, 01:31 PM
Solid Biosciences shares are trading lower after the company reported worse-than-expected Q3 EPS results. The company reported interim data from INSPIRE DUCHENNE trial.
📉 NegativeBenzinga•Nov 3, 2025, 09:50 PM
Solid Biosciences Reports Interim Data From INSPIRE DUCHENNE Trial Showing Strong Microdystrophin Expression And Muscle Biomarker Improvements
📈 PositiveBenzinga•Nov 3, 2025, 09:26 PM
Solid Biosciences Q3 EPS $(0.48) Misses $(0.43) Estimate
📉 NegativeBenzinga•Nov 3, 2025, 09:23 PM
Solid Biosciences Announces Non-Exclusive Licensing Agreement With Kinea Bio, Granting Kinea License To Utilize AAV-SLB101 As The Delivery Backbone For KNA-155
📈 PositiveBenzinga•Sep 23, 2025, 12:10 PM
Frequently Asked Questions about SLDB
What is SLDB's current stock price?
Solid Biosciences Inc. (SLDB) is currently trading at $5.94 per share. The stock has moved +12.50% today.
What is the analyst price target for SLDB?
The average analyst price target for SLDB is $12.50, based on 1 analyst.
What sector is Solid Biosciences Inc. in?
Solid Biosciences Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is SLDB's market cap?
Solid Biosciences Inc. has a market capitalization of $0.46 billion, making it a small-cap company.
Does SLDB pay dividends?
No, Solid Biosciences Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorANNX
Annexon, Inc.
$5.17
Mkt Cap: $0.6B
AURA
Aura Biosciences, Inc.
$5.86
Mkt Cap: $0.4B
AUTL
Autolus Therapeutics plc
$1.63
Mkt Cap: $0.4B
BNTC
Benitec Biopharma Inc.
$11.50
Mkt Cap: $0.3B
DSGN
Design Therapeutics, Inc.
$9.68
Mkt Cap: $0.6B
LBRX
LB Pharmaceuticals Inc Common Stock
$21.07
Mkt Cap: $0.5B
NMRA
Neumora Therapeutics, Inc. Common Stock
$1.75
Mkt Cap: $0.3B
QSI
Quantum-Si incorporated
$1.27
Mkt Cap: $0.2B
RAPT
RAPT Therapeutics, Inc.
$33.81
Mkt Cap: $0.6B
RCKT
Rocket Pharmaceuticals, Inc.
$3.23
Mkt Cap: $0.3B
Explore stocks similar to SLDB for comparison